Applied Molecular Transport reports Q4 EPS (58c), consensus (59c)

As of December 31, 2022, cash and cash equivalents were $61.1M compared to $159.8M for the year ended December 31, 2021. "We were pleased to recently present additional positive AMT-101 translational data at ECCO for our Phase 2 FILLMORE monotherapy trial in patients with chronic pouchitis," said Tahir Mahmood, chief executive officer and co-founder of AMT. "We remain focused on exploring a strategic partnership to advance AMT-101 for this important indication which has been granted Orphan Drug Designation by the FDA."